Incyte | INCY - Current Liabilities


Incyte reported $1.52B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agenus USD 287.13M 52.57M Sep/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025